Monte Rosa receives IND clearance for molecular glue degrader MRT-2359 for MYC-driven solid tumors
Sep. 7, 2022
Monte Rosa Therapeutics Inc. has received FDA clearance of its IND application for MRT-2359, a potent and selective GSPT1-directed molecular glue degrader (MGD).
